All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amikacin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Arikayce
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2021
Details:
First patient was dosed in late December, 2020, in the frontline clinical trial program of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eicosapentaenoic Acid
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Vascepa
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Amarin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 07, 2020
Details:
Study aims to evaluate effects of icosapent ethyl (VASCEPA®) (IPE) on laboratory-confirmed viral upper respiratory infection (URI) rates, clinical impact and outcomes, especially with SARS-CoV-2 infection in adults with established atherosclerotic cardiovascular disease.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
